Cargando…

A New Strategy for Rapidly Screening Natural Inhibitors Targeting the PCSK9/LDLR Interaction In Vitro

The interaction between proprotein convertase subtilisin/kexin type 9 (PCSK9) and the low-density lipoprotein receptor (LDLR) is a promising target for the treatment of hyperc-holesterolemia. In this study, a new method based on competitive affinity and tag detection was developed, which aimed to ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Li, Shen, Chen, Huang, Ya-Xuan, Li, Ya-Nan, Liu, Xiu-Feng, Liu, Xu-Ming, Liu, Ji-Hua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225438/ https://www.ncbi.nlm.nih.gov/pubmed/30235833 http://dx.doi.org/10.3390/molecules23092397

Ejemplares similares

A rapid strategy for screening high-efficiency PCSK9 inhibitors from Ginkgo biloba leaves by ligand fishing, HPLC-Q-TOF-MS and interdisciplinary assay
por: Li, Li, et al.
Publicado: (2020)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

The effect of PCSK9 immunization on the hepatic level of microRNAs associated with the PCSK9/LDLR pathway
por: Ataei, Sarina, et al.
Publicado: (2023)

PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells
por: Lagace, Thomas A.
Publicado: (2014)

PCSK9/LDLR System and Rheumatoid Arthritis-Related Atherosclerosis
por: Arida, Aikaterini, et al.
Publicado: (2021)

23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9
por: Li, Hui-hui, et al.
Publicado: (2019)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression in vitro and in vivo
por: Gu, Lili, et al.
Publicado: (2017)

The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
por: Meshkov, Alexey, et al.
Publicado: (2021)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Heterozygous Ldlr-Deficient Hamster as a Model to Evaluate the Efficacy of PCSK9 Antibody in Hyperlipidemia and Atherosclerosis
por: Wu, Yue, et al.
Publicado: (2019)

In Silico Insights into Protein–Protein Interaction Disruptive Mutations in the PCSK9-LDLR Complex
por: Martin, William R., et al.
Publicado: (2020)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations
por: Futema, Marta, et al.
Publicado: (2014)

c-IAP1 Binds and Processes PCSK9 Protein: Linking the c-IAP1 in a TNF-α Pathway to PCSK9-Mediated LDLR Degradation Pathway
por: Xu, Weiming, et al.
Publicado: (2012)

NMR, LC-MS Characterization of Rydingia michauxii Extracts, Identification of Natural Products Acting as Modulators of LDLR and PCSK9
por: Sut, Stefania, et al.
Publicado: (2022)

A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
por: Gupta, Nidhi, et al.
Publicado: (2010)

The Modulation of PCSK9 and LDLR by Supercritical CO(2) Extracts of Mentha longifolia and Isolated Piperitone Oxide, an In Vitro Study
por: Sut, Stefania, et al.
Publicado: (2021)

LDLR and PCSK9 Are Associated with the Presence of Antiphospholipid Antibodies and the Development of Thrombosis in aPLA Carriers
por: Ochoa, Eguzkine, et al.
Publicado: (2016)

A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
por: Safarova, Maya S., et al.
Publicado: (2019)

Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine
por: De Castro-Orós, Isabel, et al.
Publicado: (2016)

Asialoglycoprotein receptor 1 is a novel PCSK9-independent ligand of liver LDLR cleaved by furin
por: Susan-Resiga, Delia, et al.
Publicado: (2021)

Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021)

Polymorphisms in PCSK9, LDLR, BCMO1, SLC12A3, and KCNJ1 Are Associated with Serum Lipid Profile in Chinese Han Population
por: Li, Zheng, et al.
Publicado: (2019)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

Patients With LDLR and PCSK9 Gene Variants Experienced Higher Incidence of Cardiovascular Outcomes in Heterozygous Familial Hypercholesterolemia
por: Doi, Takahito, et al.
Publicado: (2021)

Caffeine blocks SREBP2-induced hepatic PCSK9 expression to enhance LDLR-mediated cholesterol clearance
por: Lebeau, Paul F., et al.
Publicado: (2022)

Testosterone Deficiency Promotes Hypercholesteremia and Attenuates Cholesterol Liver Uptake via AR/PCSK9/LDLR Pathways
por: Yuefeng, Yu, et al.
Publicado: (2022)

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels
por: Fruchart Gaillard, Carole, et al.
Publicado: (2022)

Allicin and Capsaicin Ameliorated Hypercholesterolemia by Upregulating LDLR and Downregulating PCSK9 Expression in HepG2 Cells
por: Nawaka, Nantiya, et al.
Publicado: (2022)

Correction to: Potentiating CD8(+) T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
por: Yuan, Juanjuan, et al.
Publicado: (2021)

Pharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
por: Choi, Jah Yeon, et al.
Publicado: (2019)

17β-Estradiol Inhibits PCSK9-Mediated LDLR Degradation Through GPER/PLC Activation in HepG2 Cells
por: Fu, Wei, et al.
Publicado: (2020)

Beneficial impact of epigallocatechingallate on LDL-C through PCSK9/LDLR pathway by blocking HNF1α and activating FoxO3a
por: Cui, Chuan-Jue, et al.
Publicado: (2020)

Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia
por: Moradi, Arman, et al.
Publicado: (2021)

Berberine: Ins and outs of a nature-made PCSK9 inhibitor
por: Ataei, Sarina, et al.
Publicado: (2022)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

Blood lipid-related low-frequency variants in LDLR and PCSK9 are associated with onset age and risk of myocardial infarction in Japanese
por: Tajima, Tomoyuki, et al.
Publicado: (2018)

Dose-dependent effects of siRNA-mediated inhibition of SCAP on PCSK9, LDLR, and plasma lipids in mouse and rhesus monkey
por: Jensen, Kristian K., et al.
Publicado: (2016)

Pcsk9 is associated with severity of coronary artery lesions in male patients with premature myocardial infarction
por: Gao, Jing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fkupqb7ierjv9n8c73m5sotauf